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Summary.- As a continuation of a previous controlled trial using "high-dose"
metronidazole as a specific sensitizer of hypoxic cells, we used a more efficient
nitroimidazole derivative (misonidazole, MISO) in combination with higher doses of
radiation in patients with supratentorial high-grade astrocytomas. Sixty-six patients
were stratified according to functional level and histological grading, and randomly
allocated within 2 weeks of operation to 1 of 3 therapeutic groups: 1, conventional
radiation alone; 2, large fractions of radiation with high-dose metronidazole;
and 3, radiation as in Group 2 but with equitoxic doses of MISO.
We examined survival as the principal end-point of the study.
Neither by increasing the dose of radiation over the previous study, nor by using a
more efficient sensitizer, were we able to improve survival over the current
conventional daily fractionated radiation.
WE HAVE SHOWN in a previous clinical
controlled study (Urtasun et al., 1976a)
that the 5-nitroimidazole compound
metronidazole, in combination with exter-
nal radiation, improved the time to
tumour regrowth in patients with supra-
tentorial glioblastomas. This was observed
under the strict limitations of the study
design, by which both the control and the
experimental groups received less than
optimal scheduling of radiation and rela-
tively low total tumour dose of radiation.
The next logical step was to proceed with
another study, in order to compare the
best currently available treatment to the
unconventional large-fraction radiation
(proved to be successful when combined
with metronidazole) but combined with a
more efficient radiosensitizer.
Nitroimidazole compounds are known
to radiosensitize mammalian cells select-
ively under acutely hypoxic in vitro
conditions (Chapman et al., 1973; Asquith
et al., 1974) and also to radiosensitize
hypoxic cells from various animal tum-
ours (Rauth, 1974). Metronidazole was
chosen in 1973 for clinical studies as a
radiosensitizer, anditstoxicity andpharm-
acological properties at oral high doses has
been previously reported (Urtasun et al.,
1974, 1975; Deutsch et al., 1975). Misoni-
dazole, a 2-nitroimidazole derivative (1-(2-
nitroimidazol - 1 -yl) - 3 - methoxypropan-
2-ol; Ro-070582; NSC-261037, MISO) has
been shown to be a more efficient radio-
sensitizer of hypoxic mammalian tumour
cells, both in vitro and in vivo (Adams
et al., 1978; Brown, 1975; Denekamp et al.,
1975; Fowler et al., 1974; Rauth et al.,
1975). Both drugs are known to produce
CNS and peripheral neurotoxicity as
major side effects when used at the high
doses necessary to produce radiosensitiza-
tion, and this has become the dose-limiting
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factor (Urtasun et al., 1976b, 1978; Dishe et
al., 1978; Wasserman et al., 1979; Thomas
et al., 1980; Frytak et al., 1978).
As in the previous study, we chose
patients with glioblastoma multiforme,
primarily because of the high rate of local
radiation failure, and the small thera-
peutic gains obtained on combining
radiation with currently available cancer
chemotherapy agents (Walker et al., 1978;
EORTC, 1978; Edwards et al., 1980;
Chang et al., 1982) and secondarily because
of the characteristic of glioblastoma to
form multiple areas ofnecrosis surrounded
by non-proliferating tumour cells, which
are assumed to be hypoxic and radio-
resistant (Hoshino et al., 1972).
In the present study, we have included
patients with astrocytoma with anaplastic
foci (AAF, Grade III astrocytoma), who
comprised 25% of all patients entered in
our study. This group of patients has a
more favourable prognosis than patients
with glioblastomas (Nelson et al., in press)
and therefore all patients were stratified
according to the histological type. They
were also stratified by the functional
neurological status.
The therapeutic results with supraten-
torial high-grade astrocytomas have been
poor, though small gains have been made
in the past 5 years, by combining
chemotherapy and radiation to achieve
median survivals of 36-42 weeks when all
histological types are considered (glioblas-
tomas as well as AAF; Walker et al., 1978;
EORTC, 1978; Edwards et al., 1980;
Chang et al., 1982).
MATERIALS AND METHODS
The centre where the study was conducted
serves a population of 1 million. All
patients with brain tumours arising from this
population are referred to this centre. A
neuropathologist assigned to the study
reviews and confirms all the pathological
slides. Only tumours showing the character-
istics of glioblastoma multiforme or astro-
cytoma wNith aniaplastic foci (AAF) were
included. All patients, were treated by 1
radiation oncologist. Ten to 14 days after
operation, and before randomization, we
stratified the patients according to functional
Karnofsky status (over 7000. Group A or
30-69%, Group B) and to histological type
(glioblastoma vs AAF). At, the time of
entering the study, 7700 were considered as
Group A and 23% as Group B. Seventy-five
per cent were glioblastomas and 250/ AAF.
Patients wNere then randomized to receive
either conventional radiation alone, metro-
nidazole plus radiation, or MISO plus
radiation.
We chose length of remission and patient
survival as the end-points, and used CT scans,
clinical performance, and dexamethasone
iequirements as criteria to establish tumour
relapse.
Treatmtent yroups
Group 1.- Radiation alone. We treated the
patients with megavoltage y-radiation from a
cobalt-60 source, delivering a total mid-plane
tumour dose of 58 Gy in 30 daily fractions, 5
days per weeks in an overall time of 6 weeks,
using large parallel opposed fields including
2/3 ofthe brain volume (tumour plus generous
margin ofnormal brain, in order to cover any
possible microscopic extensions).
Group 2.-Radiation plus metronidazole
(METRO). We used the same source and the
same volume and technique of radiation, but
the treatments were delivered in 9 large
fractions of 4-33 Gy 3 timess weekly in an
overall time of 3 weeks.
METRO* was given orally at a dose of
6 g/m2 4 h before each radiaton fraction in the
form of500mg capsules.
Group 3.-Radiation plus MISO. The
radiation treatment was delivered as des-
cribed in Group 2. MISOt wNas given in the
form of 500mg capsules, administered by
mouth at a dose of 1-25 g/m2 4 h before
each radiation fraction.
All patients receiving the nitroimidazole
compounds wNere restricted to clear fluids b,
mouth for 7 h before drug administration, to
avoid interference with drug absorption.
Prochlorperazine (Stemetil), 10 mg by moutlh,
was administered 2 h before drug ingestion
as an antiemetic. All patients were placed on
*KinLdly supplied by Pouleiuc, Mlointreal, Caniada.
tKindly supplied by Hoffman LaRoche, Montreal, Cainada.
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TABLE I.-Patient composition of Group I-conventional radiation (control), Group II-
Metronidazole plus radiation and Group III-Misonidazole plus radiation
Age (Mean+ s.d.)
No.
Surgery (%)
Subtotal
Biopsy only
Functional status (%)
Karnofsky> 70
Karnofsky 30-69
AAF
Glioblastoma
Tumour location (%)
Parietal
Other
Group I Group II
55-4+ 10-99 56+9-62
19 17
19-8
10-1
21 -4
8-9
7-1
23 -2
12-5
17 -8
dexamethasone, (Decadron) 9-16 mg daily, at
the beginning and for the duration of
treatment and then reduced slowly.
CT scans of the brain were performed
before and after operation, mid-way through
treatments and at monthly intervals until
tumour regrowth. Tumour volume, mid-line
shift, degree of tumour augmentation and
ventricular dilatation were entered in a
computer programme for analysis. We con-
sidered a patient to have achieved a complete
response when there was complete disappear-
ance of direct visual evidence of tumour and
absence of mass effect on CT scan, while
showing improvement of all clinical neuro-
logical signs and symptoms and being off
dexamethasone. A partial response was when
on CT scan there was over 50% reduction of
tumour volume and improvement of mass
effect, while showing improvement of neuro-
logical signs and symptoms and on decreasing
doses of dexamethasone. We considered a
patient in relapse when there was CT-scan
evidence ofincreased tumour volume (tumour
enhancement peritumoral oedema) while
showing a worsening in clinical status (drop of
15% or more in the Karnofsky scale) and
requiring doses ofdexamethasone.
The study began in August 1976, when 66
patients entered the study and 59 fulfilled the
protocol requirements and formed the basis of
this report. Five patients were ineligible
because of wrong histology, and 2 refused to
begin treatment. Table I shows group
comparability according to age, histological
type, functional status and tumour location.
At the time of documented relapse, we
started the patients on CCNU (a nitrosurea
compound) at the single dose of 80 mg/M2
12 *5
17-8
25
5 -3
8 9
21 -4
7 1
23 -2
Group III
59-37+8-79
23
30 3
8-9
30 3
8 9
8 -9
30 3
23-2
16 -0
orally every 4-5 weeks, provided the WBC
was >4000 and platelet count > 105. The dose
was halved if the WBC was 2000-4000 or
platelet count 7-10 x 104. Treatments were
temporarily discontinued when either the
WBC was <2000 and platelet count < 7 x 104,
or there was evidence of pulmonary toxicity.
We measured concentrations of the nitro-
imidazole compounds in blood at the time of
irradiation (4 h after drug ingestion) and
whenever possible a 24h drug-kinetic study
in blood was performed at the beginning of
the 3-week treatment. Measurements used
the high-performance liquid chromatography
technique ofWorkman et al. (1978).
Before the patients were entered into the
study, normal liver-function and renal-
function tests and normal peripheral haem-
atological values were required. These tests
included blood determinations of alkaline
phosphatase, serum glutamic oxalacetic trans-
aminase, bilirubin, blood urea nitrogen,
creatinine, uric acid, WBC counts, platelet
count, haemoglobin and haematocrit. All tests
were done twice weekly during administration
of the nitroimidazole compounds, and there-
after at each follow-up.
Whenever possible, necropsies were per-
formed and the brain specimen referred to the
neuropathologist assigned to the study.
RESULTS
Six patients, 2 on each arm, had major
protocol violations because of refusal to
receive CCNU at the time of tumour
relapse. Ten patients required dose modifi-
cations of the nitroimidazoles, due mainly
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TABLE II.-Comparative toxicity to treatment in the 3 experimental arms
Nausea and vomiting
Peripheral neuropathy
CNS symptoms*
Ototoxicity
Hypersensitivity (dermatitis)
Dose modifications
Group I
Control
(19)
1
0
8
0
it
0
Group II
METRO
(17)
8
0
5
1
1
8
Group III
MISO
(23)
5
0
3
2
3
2
* Include ataxia, shuffling gait, tremors and somnolence.
t Dermatitis related to Dilantin.
TABLE III.-Tumour response rates 1 month after-treatment, using CT scan, clinical
evaluation and requirementfor Dexamethasone
Complete
Partial
No change
Progression
Overall response
Group I (19)
No. %
0 0
3 16
9 47
7 37
3 16
to acute gastrointestinal (GI) toxicity, 8 in
the METRO group and 2 in the MISO
group. All these 16 patients are included in
the final evaluation.
Ten patients died during the first 4
weeks after completion of treatment; 2 in
Group 1, and 4 in Groups 2 and 3; 1 in each
group, due to causes unrelated to the
treatment or to the tumour (myocardial
infarction and pulmonary emboli) and the
rest due to tumour progression and gross
cerebral oedema. One patient in Group 2
was in the favourable histological and
functional groups (AFF and Karnofsky
over 70%), a second patient was also an
AAF but below 60% on the Karnofsky
status. A third patient was lost to follow-
up at 60 days and therefore considered
dead. In Group 3, 3 patients had glio-
blastomas with 2 of them in the
favourable, and 1 in the unfavourable
functional group. All 10 patients are
included in the study for the final survival
analysis.
Of the 59 evaluable patients, 75% were
glioblastomas and 25% were considered in
the unfavourable functional group. The
mean age for the entire population of
patients was 58 years. Ten, 5 and 4% of
patients in Groups 1, 2 and 3, respectively,
were less than 40 years old and 36, 35 and
50% respectively were over 60 years old.
METRO toxicity consisted mainly of
nausea and vomiting and CNS symptoms
of encephalopathy (ataxia, shuffling gait,
somnolence and seizure activity: Table
II).
The mean (+ s.d.) plasma concentra-
tions at 4 h after ingestion was 165 + 49-4
,ug/ml (range 24-356) for METRO and
38-8 + 16'3 Pg/ml (range 8-145) for MISO.
Plasma half-life was 7'8 + 3-4 h in 14
patients taking METRO and 10 + 3-8 h in
13 patients taking MISO.
The overall response rate at 1 month
after treatment was 16% for the control
group, 12% for the METRO group and
21% for the MISO group (Table III).
There were no complete responders and all
3 groups had similar numbers of partial
response.
The observed median length of remis-
sion (first day oftreatment to relapse) was
175 days for Group 1, 107 days for Group 2
and 157 days for Group 3. No statistical
differences among the 3 arms were
found (log-rank P=0*10). The Kaplan-
Meier survival plots (Kaplan, 1958) shown
Group II (17)
No. %
0 0
2 12
10 58
5 29
2 12
Group III (24)
No. %
0 0
5 21
11 46
8 33
5 21
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tumour tissue and necrotic material. We
were unable to find any areas of demye-
lination, suggesting normal-tissue damage
by radiation in those patients receiv-
ing concomitant nitromidazoles and radia-
tion.
Drug toxicity
Nausea and vomiting, as well as CNS
symptoms, were more prevalent in the
patients treated with METRO (Table II)
100 200 300 400 500 DAYS and more patients in this group required
Iaplan-Meier survival plots showing drug modification (50% vs 20% forMISO).
bability of survival with time for There was no evidence of peripheral
s. There was no difference between neuropathy, and there were no short-term
changes in the renal- or liver-function test
live Dead Total Median and no changes in the peripheral-blood
2 17 19 180-7 26 weeks v.
3 14 17 135-7 19 weeks values, suggesting marrow toxicity.
1 22 23 191 4 27weeks CCNU toxicity consisted of moderate
-Gehan, P=0-87. leucopenia and thrombocytopenia, neces-
test,P=0-99. sitating occasional drug adjustments. We
were unable to detect any instance of
'igure, indicate no differences pulmonary toxicity. Some of the patients
the 3 survival curves, using the (10%) developed a reversible moderate
-Gehan test statistic (P=0.87); fall in haemoglobin levels.
DISCUSSION
On completing our previous study on
the use of radiation and METRO in
glioblastomas (Urtasun et al., 1976a) we
concluded that further clinical studies
were warranted in view of the observed
positive results.
We chose to continue the work with this
type of tumour by increasing the dose of
radiation per fraction and by using a more
effective sensitizer of hypoxic tumour
cells. We administered the new radiosensi-
tizer MISO to our patients at a total dose
that we considered equitoxic to the
previously used METRO (11 25 g/m2 vs
54 g/m2 respectively). The maximum total
dose of MISO, beyond which there is an
unacceptably high incidence of neuro-
toxicity, is 12g/m2 (Dishe et al., 1978;
Wasserman et al., 1979). As in the previous
study, we used the same unconventional
large fractions of radiation (3 times per
week) combined with relatively large doses
of the sensitizer, because ofinference from
in vitro studies and animal tumour models
and the log-rank test (P= 0.99) confirms
the visual impression that there were no
differences between the 3 groups. The
median survival was 26 weeks for Group 1,
19 weeks for Group 2, and 27 weeks for
Group 3. Survival at one year was 16%,
6% and 25% for each group respectively.
Analysis of the 1-year survivors on
Group 3 reveals 3 patients with glioblasto-
mas and 2 with AAF. All 5 were in the
favourable functional group, and the mean
age (58) was similar to that of the whole
population in the study (15% < 40 years
and 65% > 60 years).
Analysis of the whole group of 1-year
survival revealed that 50% were glio-
blastomas (vs 75% for all patients) and
over 95% were in the favourable func-
tional group.
Our necropsy rate was 3000. Residual
tumour was present in all specimens.
There were no instances oftumour extend-
ing beyond the volume ofradiation, either
by direct extension or by intraventricular
seeding. All had diffuse cerebral oedema
plus gross residual mass composed of
-4
cc .6-
0 =
-
0.1-
FIGURE.-K
the pro
patient,
the 3 cu
Al Group
* I
A II
* III
Wilcoxon-
Log-rank I
in the iF
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then available, that a larger radiosensitiza-
tion would probably be seen with this
approach. We wanted to compare our
experimental approach to the currently
best, accepted method of treating glio-
blastomas; therefore a control group of
patients from the same population was
treated at our institution with daily
conventional fractionation. All patientts
received systemic chemotherapy in the
form of CCNU at t,he time of tumour
progression. XVe have found no statistical
difference in the median survival time
between the 3 groups of patients (Figure)
indicating that the combination of radia-
tion at large doses per fraction with either
METRO or MISO offers no clear advan-
tage over conventional daily fractionated
radiotherapy alone.
This was also seen in the patients in
whom we measured the length of remis-
sion, though using this end-point the
number of patients was considerably
reduced because about half ofthe patients
failed to obtain a measurable response.
It should be noted that in our previous
publication (Urtasun et al., 1 976a) the
Kaplan-Meier survival curves never cros-
sed one another, whereas in the present
study they do, and when this happens with
small data sets the statistical tests are
bound to be inconclusive. Because of this,
we are only able to observe that we are
seeing no differences in an improvement at.
a 60-700/ level, but might be unable to
detect a 20-300o improvement which
clinically could be significant.
In comparing the present results with
those of the previously reported study
(Urtasun et al., 1976a) it is also apparent
that neither by increasing the size of the
radiation fractions (from 3 33 to 4 33 Gy)
nor by using a more efficient radiosensi-
tizer (MISO) were we able to improve the
results of the original study. The METRO
group in the present studv appears to be
fairing even worse.
A detailed comparison of therapeutic
effectiveness (toxicity and survival)
among the group of patients treated with
nitroimidazole drugs shows that MISO
appears to hav-e an advantage over
METRO. Not only did the MISO group of
patients have a lower incidence ofacute GI
and CNS toxicity, but there also appears
to be a small difference (though not
statistically significant) in the 1-year
survival and the median survival times. Of
the MIISO-treated patients, 25% survived
over 1 year, against 6% of the METRO
group. The median survival time of 27
weeks for the MISO group contrasts with
the 19 weeks for the METRO group. It is
true, of course, that these differences are
observed because of the unexplained poor
survival of patients in the METRO-
treated group. This contrasts with the 26-
weeks median survival in the previously
published METRO study, even though a
lower dose ofradiation was then used. This
difference disappears, however, if we use
only patients surviving at least 4 weeks
after treatment for analysis. Using this
criterion, the median survival for the
present METRO group is 28 weeks, for the
MISO group, 34 weeks, and for the
previous METRO study, 26 weeks. The
favourable prognostic factors (AAF,
Karnofsky over 700o and age below 40
years were equally distributed among the
present MISO and METRO groups.
As previously reported, both the histo-
logical type and functional status are
important prognostic factors (Nelson et al.,
in press; Sheline et al., 1982). In our study,
this was confirmed when the patients
surviving more than a year were analysed.
Fifty per cent of these patients were AAF
(vs 250o incidence of the whole study).
Similarly, 95% of these patients had a
favourable functional status (compared to
78% in the whole study).
Of interest is the fact that we found no
peripheral neuropathies secondary to
either drug, though we had expected
25-300/ in the patients treated with
MISO. We assuime that this was probably
because all patients were on high-dose
dexamethasone while receiviiig these
drugs. Dexamethasone concurrently with
MISO has been reported to decrease the
incidence of MISO-induced peripheral
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neuropathy (Wasserman et al., 1980;
Workman, 1982; Bleehen, 1980; Walker &
Strike, 1980; Urtasun et al., in press). Only
45% of the patients receiving nitro-
imidazoles were on phenytoin. Two
patients with no evidence of previous
seizures developed seizure activity prob-
ably related to METRO and were placed
on phenytoin, with improvement; in the
MISO group, one patient who had pre-
vious seizures and had been on phenytoin
developed repeated seizures.
Our overall median survivals are clearly
inferior (all groups < 26 weeks) to those
reported in the literature with conven-
tional multidisciplinary approach (Walker
et al., 1978; EORTC, 1978; Edwards et al.,
1980; Chang et al., 1982) (range 36-45
weeks) and to those reported using large
fractions of radiation and MISO (Bleehen
et al., 1980; Carabell et al., 1981; Kogelnik,
1980). This is so, even ifwe eliminate from
the analysis the 10 patients who survived
less than 4 weeks after completion of
treatment. We have no reasons to explain
this difference of results between our
control population (conventional treat-
ment) and those ofother centres. Although
our volume ofirradiation was slightly less
than the whole brain, which is commonly
used in some of the other centres, our
treatment planning was done using CT
scans, and a review of our necropsy
material failed to reveal any instance
where tumour was extending beyond the
field of irradiation. This is in agreement
with recent reports recommending the
irradiation of less than the whole brain
(Sheline et al., 1982). The total dose of
radiation was 2 Gy less than in other
studies (58 Gy) in 30 fractions for our
control group vs 60 Gy in 30-33 fractions
in other studies) and this is unlikely to
influence the results significantly. It
should be noted that 25% of our total
population of patients were in the poor
Karnofsky functional levels 30-69%). On
the other hand, the proportion of glio-
blastomas in our patient population (75%)
was similar to that reported by others.
From the present study we are unable to
substantiate the predictions from our
earlier study, that a large therapeutic
improvement could be obtained by com-
bining large fractions of radiation with
nitroimidazoles in patients with malignant
gliomas.
This work was supported by Grant No. 55-45033
from the National Cancer Institute of Canada and
Grant No. 5236 Alberta Heritage Foundation for
Medical Research. The secretarial help of Miss Lisa
Skoreyko is greatly appreciated.
REFERENCES
ADAMS, G. E., FOWLER, J. F. & WARDMAN, P. (Eds)
(1978) Hypoxic cell sensitizers in radiobiology and
radiotherapy. Br. J. Cancer, 37, (Suppl. III).
AsQUITH, J. C., FOSTER, J. L., WILLSON, R. L.,
INGS, R. & McFADZEAN, J. A. (1974) Metroni-
dazole ("Flagyl"): A radiosensitizer of hypoxic
cells. Br. J. Radiol., 47, 474.
BLEEHEN, N. M. (1980) The Cambridge glioma trial
of misonidazole and radiation therapy with asso-
ciated pharmacokinetics. Cancer Clin. Trials, 3,
267.
BROWN, J. M. (1975) Selective radiosensitization of
the hypoxic cells ofmouse tumours with the nitro-
midazoles metronidazole and R07-0582. Radiat.
Res., 64, 1975.
CARABELL, S. C., BRUNO, L. A., WEINSTEIN & 4
others (1981) Misonidazole and radiotherapy
to treat malignant glioma: A phase II trial of the
radiation therapy oncology group. Int. J. Radiat.
Oncol. Biol. Phys., 7, 71.
CHAPMAN, J. D., REUVERS, A. P. & BORSA, J. (1973)
Effectiveness of nitrofuran derivatives in sensiti-
zing hypoxic mammalian cells to X-rays. Br. J.
Radiol., 46, 623.
CHANG, C. H., SCHOENFELD, D., HORTON, J.,
SALAZAR, O., PEREZ TAMAYO, R. & KRAMER, S.
(1982) Comparison of post-operative radiotherapy
and chemotherapy in the multidisciplinary man-
agement of gliomas. Cancer (in press).
DENEKAMP, J. & HARRIS, S. R. (1975) Tests of two
electron-affinic radiosensitizers in vivo using
regrowth of experimental carcinoma. Radiat.
Res., 61, 191.
DEUTSCH, G., FOSTER, J. L., McFADZEAN, J. A. &
PARNELL, M. (1975) Human studies with "high
dose" metronidazole: A non-toxic radiosensitizer
of hypoxic cells. Br. J. Cancer, 31, 75.
DISCHE, S., SAUNDERS, M. I., ANDERSON, P. & 6
others (1978) The neutrotoxicity of mison-
idazole: Poollirig of data from five centers. Br. J.
Radiol., 51, 1023.
EDWARDS,M. S., LEVIN, V. A. & WILSON, C. B. (1980)
Brain tumour chemotherapy: An evaluation of
agents in current use for Phase II and III trials.
Cancer Treatment Rep., 64, 1179.
EORTC BRAIN TuMOUR GROUP (1978) Effect of
CNUU on survival rate of objective remission
and duration of free interval in patients with
malignant brain glioma: Final evaluation. Eur. J.
Cancer, 14, 851.
FOWLER, J. F., SHELDON, P. W. & FOSTER, L. J.
(1974) radiosensitization of hypoxic cells in solid108 R. UJRTASUN ET AL.
tumours in airbreathing C3H mice. Radiat. Res.,
59, 141.
FRYTAK, S., MOERTEL, C. G., CHILDS, D. S. &
ALBERS, J. W. (1978) Neurologic toxicity associa-
ted with high-dose metronidazole therapy. Ann.
Intern. Med., 88, 361.
HOSHINO, T., BARKER, M., WILSON, C. B., BALDREY,
E. B. & FENER, D. (1972) Cell kinetics of human
gliomas. J. Neurosurg., 37, 15.
KAPLAN, E. L. & MEIER, P. (1958) Nonparametric
estimation from incomplete observations. J. Am.
Statist. Assoc., 53, 457.
KOGELNIK, H. D. (1980) Clinical experience witlh
misonidazole. Cancer Clin. Trials, 3, 179.
NELSON, S. J., SCHOENFELD, D., TSUKADA, Y. &
FULLING, K. Histological criteria with prog-
nostic significance for malignant glioma. In
Tumours of the Central Nervous System, Modern
Radiotherapy and Multidisciplinary Management.
(Ed. Chang). New York: Mason (in press).
RAUTH, A. M., KAUFMAN, K. & THOMSON, J. E.
(1975) In vivo testing of hypoxic cell radio-
sensitizers. In Radiation Research: Biomedical,
Chemical and Physical Perspectives. (Eds. Nygaard
et al.). New York: Academic Press. p. 761.
RAUTH, A. M. (1974) In vivo testing of hypoxic cell
radiosensitizers. Radiat. Res., 59, 165.
SHELINE, G. E. (1982) Radiotherapy of adult prim-
ary cerebral neoplasms in cancer treatment and
research series In Oncology and Nervous System.
(Ed. Walker). The Hague: Martinez. (In press).
THOMAS G. M., RAUTH, M. A. & BUSH, R. S. (1980)
A toxicity study of daily dose metronidazole with
pelvic irradiation. Cancer Clin. Trials, 3, 223.
URTASUN, R. C., STURMWIND, J., RABIN, H., BAND,
P. R. & CHAPMAN, J. D. (1974) High dose metro-
nidazole: A preliminary pharmacological study
prior to its investigational use in clinical radio-
therapy trials. Br. J. Radiol., 47, 297.
URTASUN R. C., CHAPMAN, J. D., BAND, P., RABIN,
R. H., FRYER, C. G. & STURMWIND, J. (1975)
Phase I study of high-dose metronidazole: A
specific in vivo and in vitro radiosensitizer of
bypoxic cells. Radiology, 117, 129.
URTASUN, R. C., BAND, R. P., CHAPMAN, J. D. &
6 others (1976a) Radiation and high-dose metro-
nidazole in supratentorial glioblastomas. N. Engl.
J. Med., 294, 1364.
URTASUN R. C., BAND, P. R., CHAPMAN, J. D.,
FELDSTEIN, M. L., MIELKE, B. & FRYER, C.
(1976b) Misonidazole neurotoxicity. N. Engl. J.
Med., 295, 901.
URTASUN, R. C., CHAPMAN, J. D., FELDSTEIN, M. L.
& 6 others (1978) Peripheral neuropathy related
to misonidazole: Incidence and pathology, Br. J.
Cancer, 37 (Suppl. III), 271.
URTASUN, R. C., TANASICHUK, H., KozIOL, D. & 2
others (1982) The effect of dexamethasone on the
neurotoxicity of nitroimidazole compounds. In
Nitroimidazoles as Hypoxic Cell Sensitizers
(Eds. Brechia & Adams). New York: Plenum
Publishers (in press).
WALKER, M. D., ALEXANDER, E., HUNT, W. E. & 9
others (1978) Evaluation of BCNU and/or radio-
therapy in the treatment of anaplastic gliomas.
A cooperative clinical trial. J. Neurosurg., 49, 333.
WALKER, M. & STRIKE, T. A. (1980) Misonidazole
peripheral neuropathy. Cancer Clin. Trials, 3, 105.
WASSERMAN, T. H., PHILLIPS, T. L., JOHNSON, R. J.
& 6 others (1979) Initial United States clinical
and pharmacologic evaluation of misonidazole
(Ro-07-0582): A hypoxic cell sensitizer. Int. J.
Radiat. Oncol. Biol. Phys., 5, 775.
WASSERMAN, T. H., PHILLIPS, T. L., VAN RAALTE &
6 others (1980) Neurotoxicity of misonidazole:
Potential modifying role of phenytoin sodium and
dexamethasone. Br. J. Radiol., 53, 172.
WORKMAN, P., LITTLE, C. J., MARTEN, T. R. & 4
others (1978) Estimation of the hypoxic cell sensi-
tizer misonidazole and its 0-demethylated meta-
bolite on biological materials by reversed-phase
high-performance liquid chromatography. J.
Chromatogr., 145, 507.
WORKMAN, P., (1980) Drug interactions with miso-
nidazole: Effects ofdexamethasone and its deriva-
tives on the pharmacokinetics and toxicity of
misonidazole in mice. Biochem. Pharmacol., 29,
2769.